JP2024516297A5 - - Google Patents

Info

Publication number
JP2024516297A5
JP2024516297A5 JP2023567994A JP2023567994A JP2024516297A5 JP 2024516297 A5 JP2024516297 A5 JP 2024516297A5 JP 2023567994 A JP2023567994 A JP 2023567994A JP 2023567994 A JP2023567994 A JP 2023567994A JP 2024516297 A5 JP2024516297 A5 JP 2024516297A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
anhedonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516297A (ja
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed filed Critical
Priority claimed from PCT/IB2022/054085 external-priority patent/WO2022234457A1/en
Publication of JP2024516297A publication Critical patent/JP2024516297A/ja
Publication of JP2024516297A5 publication Critical patent/JP2024516297A5/ja
Pending legal-status Critical Current

Links

JP2023567994A 2021-05-04 2022-05-03 うつ病の治療のための組成物及び方法 Pending JP2024516297A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/307,858 2021-05-04
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US17/670,123 2022-02-11
US202263313792P 2022-02-25 2022-02-25
US63/313,792 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (2)

Publication Number Publication Date
JP2024516297A JP2024516297A (ja) 2024-04-12
JP2024516297A5 true JP2024516297A5 (https=) 2025-05-13

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567994A Pending JP2024516297A (ja) 2021-05-04 2022-05-03 うつ病の治療のための組成物及び方法

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Similar Documents

Publication Publication Date Title
JP2024516297A5 (https=)
US10682354B2 (en) Compositions and methods
US8304431B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
TWI330083B (en) Methods for treating or preventing symptoms of hormonal variations
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
JP2010535801A5 (https=)
EP0591434A1 (en) Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JP2024507638A (ja) 性機能障害処置のための神経刺激性ステロイドの使用
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
US20040092519A1 (en) New treatment for hot flashes
JP2011502175A (ja) 非定型抗精神病薬の使用に関連した体重増加を遅延させるための方法および組成物
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
Chen et al. A review of treatment modalities for comorbid neuropathic pain and depression
EP3180015A1 (en) Methods of treating depression using nmda modulators
McManis et al. Nausea and vomiting associated with selective serotonin reuptake inhibitors: incidence, mechanisms and management
US10300068B2 (en) Method of treating insomnia
JP2005511615A (ja) 神経伝達物質均衡の化学療法
Oettmeier et al. The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects
TWI355935B (en) Combination of a taxane and a cyclin-dependent kin
MX2011001631A (es) Tratamiento de transtornos de ansiedad.
Howland Therapeutic armamentarium for treating depression
JP2002524509A (ja) 新規組成物
KR20000029647A (ko) 양극성장애의치료방법
JPH0840903A (ja) 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物